JP2005510251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510251A5 JP2005510251A5 JP2003547966A JP2003547966A JP2005510251A5 JP 2005510251 A5 JP2005510251 A5 JP 2005510251A5 JP 2003547966 A JP2003547966 A JP 2003547966A JP 2003547966 A JP2003547966 A JP 2003547966A JP 2005510251 A5 JP2005510251 A5 JP 2005510251A5
- Authority
- JP
- Japan
- Prior art keywords
- sarcoidosis
- subject
- gene
- expression level
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 111
- 230000014509 gene expression Effects 0.000 claims description 91
- 201000000306 sarcoidosis Diseases 0.000 claims description 88
- 108090000623 proteins and genes Proteins 0.000 claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 229920001184 polypeptide Polymers 0.000 claims description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
- 239000012472 biological sample Substances 0.000 claims description 50
- 108020004999 messenger RNA Proteins 0.000 claims description 44
- 239000000523 sample Substances 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 18
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000000636 Northern blotting Methods 0.000 claims description 8
- 238000011529 RT qPCR Methods 0.000 claims description 8
- 238000003757 reverse transcription PCR Methods 0.000 claims description 8
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 5
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims 7
- 238000001262 western blot Methods 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000002493 microarray Methods 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 3
- 206010036790 Productive cough Diseases 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 210000002726 cyst fluid Anatomy 0.000 claims 3
- 210000002751 lymph Anatomy 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 208000024794 sputum Diseases 0.000 claims 3
- 210000003802 sputum Anatomy 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 102000005228 Cyclic AMP Response Element Modulator Human genes 0.000 claims 2
- 108010056281 Cyclic AMP Response Element Modulator Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108010092574 CD69 antigen Proteins 0.000 claims 1
- 101150028299 CD69 gene Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 101710082744 T-cell receptor alpha chain C region Proteins 0.000 claims 1
- 102000005747 Transcription Factor RelA Human genes 0.000 claims 1
- 108010031154 Transcription Factor RelA Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 102000052620 human IL10 Human genes 0.000 claims 1
- 102000047410 human NFKB1 Human genes 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- -1 small molecule compound Chemical class 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 description 1
- 206010020094 Hilar lymphadenopathy Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33426401P | 2001-11-29 | 2001-11-29 | |
| PCT/EP2002/013448 WO2003046578A2 (en) | 2001-11-29 | 2002-11-28 | Method for the assessment and prognosis of sarcoidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005510251A JP2005510251A (ja) | 2005-04-21 |
| JP2005510251A5 true JP2005510251A5 (https=) | 2006-01-19 |
Family
ID=23306395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547966A Pending JP2005510251A (ja) | 2001-11-29 | 2002-11-28 | サルコイドーシスの評価法と予後判定法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050032062A1 (https=) |
| EP (1) | EP1454145A2 (https=) |
| JP (1) | JP2005510251A (https=) |
| AU (1) | AU2002364277A1 (https=) |
| WO (1) | WO2003046578A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007512835A (ja) * | 2003-12-05 | 2007-05-24 | アンジオジェネティクス・スウェーデン・エイ・ビー | 新脈管形成に影響を与えるポリペプチド、タンパク質及び組成物、及びそれを使用する方法 |
| WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
| JP4512828B2 (ja) * | 2005-04-12 | 2010-07-28 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| WO2010151599A1 (en) * | 2009-06-23 | 2010-12-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Human leukocyte antigen alleles associated with advanced lung diseases |
| US20110111437A1 (en) * | 2009-10-08 | 2011-05-12 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomarkers For Prognosis of Pulmonary Diseases |
| JP5120570B2 (ja) * | 2010-02-15 | 2013-01-16 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP5574348B2 (ja) * | 2012-05-31 | 2014-08-20 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| WO2016141347A2 (en) * | 2015-03-04 | 2016-09-09 | Wayne State University | Systems and methods to diagnose sarcoidosis and identify markers of the condition |
| WO2022174067A1 (en) * | 2021-02-11 | 2022-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods relating to anti-il-1 therapy and anti-il-6 therapy and hypersensitivity |
| WO2025230589A1 (en) * | 2024-04-29 | 2025-11-06 | Wayne State University | Peptide-based sarcoidosis immunodiagnostics |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014067A1 (en) * | 1992-12-14 | 1994-06-23 | T Cell Sciences, Inc. | Diagnosis and therapy of sarcoidosis |
-
2002
- 2002-11-28 EP EP02799048A patent/EP1454145A2/en not_active Withdrawn
- 2002-11-28 AU AU2002364277A patent/AU2002364277A1/en not_active Abandoned
- 2002-11-28 JP JP2003547966A patent/JP2005510251A/ja active Pending
- 2002-11-28 US US10/497,349 patent/US20050032062A1/en not_active Abandoned
- 2002-11-28 WO PCT/EP2002/013448 patent/WO2003046578A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510251A5 (https=) | ||
| JP6430560B2 (ja) | 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７ | |
| AU2021273299B2 (en) | Protein markers for assessing alzheimer's disease | |
| JP2005520479A (ja) | 乾癬の確認、評価、予防および治療のための組成物、キットおよび方法 | |
| KR20110057188A (ko) | 바이오마커 프로파일 측정 시스템 및 방법 | |
| KR20160117606A (ko) | 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험 | |
| US20200232925A1 (en) | Immunoassays for detection of ran proteins | |
| JP2005510251A (ja) | サルコイドーシスの評価法と予後判定法 | |
| JPWO2003014395A1 (ja) | 気管支喘息の検査方法 | |
| US20230083393A1 (en) | Multiple biomarkers for diagnosing lung cancer and use thereof | |
| JPWO2002052006A1 (ja) | アレルギー性疾患検査方法 | |
| Noh et al. | MAP17 is associated with the T‐helper cell cytokine‐induced down‐regulation of filaggrin transcription in human keratinocytes | |
| JP5704684B2 (ja) | ＩｇＧ４関連疾患診断用マーカー及びその利用 | |
| CN118667940A (zh) | Ifp35和/或nmi在诊治银屑病中的应用 | |
| KR20250044214A (ko) | Covid-19 중증도 예측 및 경과 모니터링 방법 | |
| Butbul Aviel et al. | A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity | |
| Al-Saffar et al. | Study the association of IRAK1 gene polymorphism and some immunological markers with the risk of rheumatoid arthritis incidence in sample of Iraqi patients | |
| US6962776B2 (en) | Methods and materials for evaluating cardiovascular conditions | |
| CN115873936B (zh) | 生物标志物cxcl8及其应用 | |
| JP7083757B2 (ja) | ドライアイ疾患の予後のための遺伝子シグネチャー | |
| KR20240136713A (ko) | 유방암의 골전이 예측 또는 진단용 조성물 및 이를 포함하는 키트 | |
| KR102089032B1 (ko) | 보체 성분 c8 감마를 이용한 알츠하이머병의 진단방법 | |
| CN110499366B (zh) | Pi15作为骨关节炎标志物的应用 | |
| JP2022516117A (ja) | ヘリコバクターピロリ連関疾患に対する遺伝子マーカー | |
| US20040058351A1 (en) | Method of examining for allergic disease |